Servier Australia and BioCurate have struck an agreement to share commercial and scientific expertise with the aim of accelerating the discovery of new therapeutics and drugs. Servier and BioCurate will collaborate under the terms of a memorandum of understanding (MOU), whereby they will work together, both directly and via participation in BioCurate’s Industry and Scientific Advisory Committee, in providing advice and assessing new therapeutic candidates arising from BioCurate’s academic partners. The signing of this MOU provides further endorsement from industry of BioCurate’s collaborative approach and its capability in improving the quality of early stage research for a successful translation into therapeutic solutions for the benefit of patients. Servier is an international pharmaceutical laboratory run by a Foundation, with its headquarters in Suresnes in France. With a solid international footing in 149 countries and revenues of €4.2 billion in 2018, Servier employs 22 000 people around the globe. Wholly independent, […]